Differential expression of stem cell markers in proliferating cells in glioma
Standard
Differential expression of stem cell markers in proliferating cells in glioma. / Rehfeld, Marten; Matschke, Jakob; Hagel, Christian; Willenborg, Kerstin; Glatzel, Markus; Bernreuther, Christian.
in: J CANCER RES CLIN, Jahrgang 147, Nr. 10, 10.2021, S. 2969-2982.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Differential expression of stem cell markers in proliferating cells in glioma
AU - Rehfeld, Marten
AU - Matschke, Jakob
AU - Hagel, Christian
AU - Willenborg, Kerstin
AU - Glatzel, Markus
AU - Bernreuther, Christian
N1 - © 2021. The Author(s).
PY - 2021/10
Y1 - 2021/10
N2 - PURPOSE: The identification of prognostically and therapeutically relevant molecular markers is fundamental to the further development of personalised therapies in brain tumours. Current therapeutic options for the treatment of gliomas rely mainly on surgical resection and the inhibition of tumour cell proliferation by irradiation and chemotherapy. Glioma stem cells are a subpopulation of proliferating tumour cells that have self-renewal capacity and can give rise to heterogeneous cells that comprise the tumour and are thought to play a role in the resistance of gliomas to therapy. The aim of this study was to evaluate the expression of markers of glioma stem cells and differentiated glial cells in proliferating glioma cells in comparison to the overall expression of the respective markers in the tumour tissue.METHODS: Tissue microarrays were assembled from specimen of pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, anaplastic oligodendroglioma, ependymoma, and anaplastic ependymoma. These were immunohistochemically double stained with antibodies against the proliferation-associated antigen Ki67 and marker proteins for glioma stem cells (CD133, Nestin, Musashi, CD15, CD44), and differentiated glioma cells (GFAP, MAP2c).RESULTS: The expression of both glial and glioma stem cell markers differs between proliferating and non-proliferating glioma cells. Furthermore, the proliferating cells in the different glial tumour entities show a different expression profile.CONCLUSION: Further analysis of marker expression in proliferating glioma cells and correlation with clinical outcome and susceptibility to irradiation and chemotherapy might help establish new biomarkers and therapies for glioma.
AB - PURPOSE: The identification of prognostically and therapeutically relevant molecular markers is fundamental to the further development of personalised therapies in brain tumours. Current therapeutic options for the treatment of gliomas rely mainly on surgical resection and the inhibition of tumour cell proliferation by irradiation and chemotherapy. Glioma stem cells are a subpopulation of proliferating tumour cells that have self-renewal capacity and can give rise to heterogeneous cells that comprise the tumour and are thought to play a role in the resistance of gliomas to therapy. The aim of this study was to evaluate the expression of markers of glioma stem cells and differentiated glial cells in proliferating glioma cells in comparison to the overall expression of the respective markers in the tumour tissue.METHODS: Tissue microarrays were assembled from specimen of pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, anaplastic oligodendroglioma, ependymoma, and anaplastic ependymoma. These were immunohistochemically double stained with antibodies against the proliferation-associated antigen Ki67 and marker proteins for glioma stem cells (CD133, Nestin, Musashi, CD15, CD44), and differentiated glioma cells (GFAP, MAP2c).RESULTS: The expression of both glial and glioma stem cell markers differs between proliferating and non-proliferating glioma cells. Furthermore, the proliferating cells in the different glial tumour entities show a different expression profile.CONCLUSION: Further analysis of marker expression in proliferating glioma cells and correlation with clinical outcome and susceptibility to irradiation and chemotherapy might help establish new biomarkers and therapies for glioma.
KW - AC133 Antigen/metabolism
KW - Biomarkers, Tumor/metabolism
KW - Brain Neoplasms/metabolism
KW - Cell Proliferation
KW - Gene Expression Regulation, Neoplastic
KW - Glioma/metabolism
KW - Humans
KW - Hyaluronan Receptors/metabolism
KW - Lewis X Antigen/metabolism
KW - Neoplastic Stem Cells/metabolism
KW - Nerve Tissue Proteins/metabolism
KW - Nestin/metabolism
KW - RNA-Binding Proteins/metabolism
U2 - 10.1007/s00432-021-03704-5
DO - 10.1007/s00432-021-03704-5
M3 - SCORING: Journal article
C2 - 34170383
VL - 147
SP - 2969
EP - 2982
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 10
ER -
